ROR1 and B-cell chronic lymphocytic leukemia: The regulation was even observed in vivo as a gene set enrichment analysis showed that pre-treatment CLL samples displayed a higher expression of genes associated with activation of RAC1 or RHOA than matched samples after treatment with the ROR1-blocking antibody cirmtuzumab [112].